amy-101

Small moleculeexperimental

Clinical trial activity

3 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Apr 24, 2017 (NCT03316521)

Timeline

2010s

Jan 1, 2017
Earliest Phase 1 Sponsor(trial)

2020s

Jan 1, 2020
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Complement C3INHIBITOR
C3 inhibitor
- Complement C3 (C3) ↗

Chemistry & pharmacology

Loading structure…

SMILES

CC[C@H](C)[C@H](NC(=O)[C@H](N)CC1=CC=C(O)C=C1)C(=O)N[C@H]2CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](C)NC(=O)CN(C)C(=O)[C@H](CC4=CNC5=C4C=CC=C5)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC6=CN(C)C7=C6C=CC=C7)NC(=O)[C@@H](NC2=O)C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)C(N)=O

Mol. weight: 1789.09 g/mol
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

NCATS4Z4DFR9BX7 ↗
ChEMBLCHEMBL4297260 ↗

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT04395456	Phase 2	Jul 31, 2020	Amyndas Pharmaceuticals S.A.
NCT03694444	Phase 1/Phase 2 (Phase 2)	Mar 31, 2019	Amyndas Pharmaceuticals S.A.
NCT03316521	Phase 1	Apr 24, 2017	Amyndas Pharmaceuticals S.A.

Showing 3 of 3 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Amyndas Pharmaceuticals S.A.	For profit	3	3	2	2017

1 organizations

Page 1 / 1